We are live on
!
Find out more
MAM
MPM Asset Management Portfolio holdings
AUM
$44.5M
Turnover
20%
1-Year Est. Return
47.28%
This Fund
S&P 500
This Quarter
Est. Return
-2.71%
1 Year Est. Return
-47.28%
3 Year Est. Return
+5.89%
5 Year Est. Return
-18.52%
10 Year Est. Return
+3.53%
AUM
$650M
AUM Growth
+$52.4M
(+8.8%)
Cap. Flow
+$115M
Cap. Flow
% of AUM
17.62%
Top 10 Holdings %
Top 10 Hldgs %
99.53%
Holding
16
New
1
Increased
–
Reduced
4
Closed
–
Avg Time Held
1.5
years
Top 10 Avg Time Held
1.5
years
Top 20 Avg Time Held
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CHMA
Chiasma, Inc. Common Stock
CHMA
|
+$141M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PETX
Aratana Therapeutics, Inc.
PETX
|
+$16.9M |
| 2 |
NEVRO CORP.
NVRO
|
+$7.02M |
| 3 |
Verastem
VSTM
|
+$1.61M |
| 4 |
EPZM
Epizyme, Inc
EPZM
|
+$1.04M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.63% |
| 2 | Miscellaneous | 1.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
Radius Health, Inc.
RDUS
| $404M | 62.17% |
5,831,253
| – | – |
2014 Q2
5 quarters
|
|
|
CHMA
2
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $113M | 17.38% |
+5,681,544
| New | +$141M |
2015 Q3
0 quarters
|
|
|
PTLA
3
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $52M | 8% |
1,220,672
| – | – |
2013 Q2
9 quarters
|
|
|
EPZM
4
DELISTED
Epizyme, Inc
EPZM
| $22.2M | 3.42% |
1,729,674
-51,412
| -3% | -$1.04M |
2013 Q2
9 quarters
|
|
5
Protara Therapeutics
TARA
$147M
| $13.7M | 2.1% |
24,585
| – | – |
2014 Q4
3 quarters
|
|
|
6
DELISTED
NEVRO CORP.
NVRO
| $9.83M | 1.51% |
211,884
-144,820
| -41% | -$7.02M |
2014 Q4
3 quarters
|
|
|
PETX
7
DELISTED
Aratana Therapeutics, Inc.
PETX
| $9.46M | 1.45% |
1,117,875
-1,000,970
| -47% | -$16.9M |
2013 Q2
9 quarters
|
|
|
TRIV
8
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
| $8.88M | 1.37% |
1,776,692
| – | – |
2014 Q2
5 quarters
|
|
9
Altimmune
ALT
$449M
| $8.44M | 1.3% |
21,159
| – | – |
2013 Q2
9 quarters
|
|
|
HSTO
10
DELISTED
Histogen Inc. Common Stock
HSTO
| $5.3M | 0.82% |
5,960
| – | – |
2013 Q3
8 quarters
|
|
11
Savara
SVRA
$978M
| $1.48M | 0.23% |
36,455
| – | – |
2014 Q1
6 quarters
|
|
|
12
Verastem
VSTM
$698M
| $1.02M | 0.16% |
47,740
-20,317
| -30% | -$1.61M |
2013 Q2
9 quarters
|
|
|
ETRM
13
DELISTED
EnteroMedics Inc.
ETRM
| $289K | 0.04% |
1,060
| – | – |
2013 Q2
9 quarters
|
|
14
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $127K | 0.02% |
22,487
| – | – |
2013 Q4
7 quarters
|
|
|
CLCD
15
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
| $84K | 0.01% |
21,806
| – | – |
2015 Q2
1 quarter
|
|
16
MacroGenics
MGNX
$211M
| $68K | 0.01% |
3,168
| – | – |
2013 Q4
7 quarters
|
|
Similar funds
WCPI
BAM
WAMC
NLVP
CIEP
IPI
CC
VSAM
MPM Asset Management's Q3 2015 Portfolio in Review
As of Q3 2015, MPM Asset Management held 16 positions worth $650M, up 8.8% from $598M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
MPM Asset Management deployed $115M of net new capital in Q3 2015, opening 1 new position. Its largest new stake was Chiasma, Inc. Common Stock: 5,681,544 shares worth $113M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Aratana Therapeutics, Inc., an estimated $16.9M trimmed.
- MPM Asset Management's largest Q3 2015 buy was Chiasma, Inc. Common Stock: 5,681,544 shares worth $113M.
- MPM Asset Management's biggest Q3 2015 reduction was Aratana Therapeutics, Inc., cutting an estimated $16.9M.
- MPM Asset Management's ten largest holdings make up 100% of its $650M portfolio in Q3 2015.
- MPM Asset Management opened 1 new position and closed 0 in Q3 2015.
- MPM Asset Management's portfolio value rose 8.8% quarter-over-quarter to $650M.
Based on MPM Asset Management's 13F filing for Q3 2015, filed 12 Nov 2015.